DexCom shares have delivered a mixed ride in recent years, and that uneven path raises a simple question for anyone looking ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM) and Wave Life Sciences (WVE) with bullish sentiments. According to TipRanks.com, Newitter ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Medical device company DexCom (NASDAQ:DXCM) announced in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96. Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...